Zydus at 390+ is too expensive. Neutraceutical companies go at 4 times sales. so AMrket cap for the company should be aroun 1000 crore instead of 1500 crores currently.
Huge investments are required in A&P to sustain the brand market share.
Any significant Upsides from these level possible only if the company is able to exponentially increase sales without significant increase in expenses. This would translate in to exponential increase in profits.
I would rather invest in the price range of 250-300 at which price the stock would be fairly valued